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Text: Background and objective: Iron accumulation within focal lesions has been described in multiple
sclerosis (MS). In early stages of the disease iron deposition may be associated with the
progression of the disease. The aim of this study is to assess the association of iron deposit in T2
focal brain lesions in patients presenting with a clinically isolated syndrome (CIS), and the
clinical/MRI diagnosis of MS.
Materials and methods: 30 patients (21 women; median age, 33.5 years; EDSS range, [0, 4.5];
mean disease duration, 3.07 months) diagnosed of CIS, underwent a 3.0 T brain MRI scan that
include proton density (PD) and T2-weighted, and susceptibility weighted (SW) sequences. Lesion
masks were obtained on PD/T2-weighted images using Jim software and registered to SW images.
Iron content of lesions was measured on filtered-phase SW images as the increase with regard to
normal appearing white matter (NAWM) values. For analysis purposes two regions of interest were
defined: PD/T2 lesion mask (ROI-1), and region with high iron content (ROI-2) defined by the region
within ROI-1 where phase values were greater than the values obtained in 17 healthy controls (15
women; median age, 35 years) for NAWM plus two SD. The measurements involved were: Fe
increase per tissue gram in ROI-1 (iFe1) and in ROI-2 (iFe2), and number of pixels in ROI-2 (NP).
In all patients we analyzed the fulfilment of MRI criteria for dissemination in space (DIS),
dissemination in time (DIT), and both dissemination in space and time (DIST). Moreover, conversion
to clinically definite MS (new relapse) was also analyzed. Statistical analysis involved Student t-test
to evaluate differences between groups in Fe measurements.
Results: Differences between the presence of a new relapse groups were found for iFe2 (yes,
25.45; no, 18.89; p=0.034), between DIS groups for NP (yes, 296.94; no, 36.14; p=0.001), between
DIT groups for iFe1 (yes, 2.37; no, -0.48; p=0.011), for iFe2 (yes, 24.10; no, 17.60; p=0.013), and
for NP (yes, 338.77; no, 50.18; p=0.003), and between DIST groups for iFe1 (yes, 2.13; no, 0.07;
p=0.048), for iFe2 (yes, 24.40; no, 18.43; p=0.032), and for NP (yes, 430.0; no, 47.85; p=0.001).
Conclusions: The results of this study suggest that some variables involving iron deposit within
visible PD/T2 lesions may be useful to discriminate CIS patients who fulfilled the criteria for
establishing the diagnosis of MS.
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